Reduce Sun Pharmaceutical Industries Ltd. at a price target of Rs 447.

Cipher Pharma Inc, along with partners Ranbaxy - a Sun Pharma firm - and Galephar Pharmaceutical Research, has entered into a patent litiga...

Ranbaxy Laboratories Inc has announced the launch of Absorica capsules in the strengths of 25 mg and 35 mg in the US market.

Ranbaxy's net loss in the April-June quarter was at Rs 186 crore ($30.94 million), compared with a loss of Rs 524 crore a year earlier.

Ranbaxy has inked a licensing pact with Cipher Pharmaceuticals Inc to exclusively market its isotretinoin capsules, used to treat acne, in ...

Ranbaxy's net sales during Q4, 2013-14 grew marginally by 1.03 per cent to Rs 2,436.1 crore, as against Rs 2,411.1 crore in the year-ago pe...

Flat growth in revenues, net loss of Rs 73.6 crore against a profit of Rs 125.7 crore in the March quarter of previous year led to a dismal...

Hopes of settlement with US Food and Drug Administration, a strong product pipeline & a discounted P/E make Ranbaxy Laboratories attractive.

At 06:35 pm; Ranbaxy pared some of the morning gains and was trading 1.9% higher at Rs 411.05.

Absorica helped Ranbaxy shore up its sales in the US market in the September quarter. The drug commands 19% market share in the US.

Ranbaxy Laboratories' US arm has received a notice from Watson Laboratories, challenging the patent of acne treatment drug Absorica.

The stock plunged over 5% on reports that the US-based Ohm Laboratories-the company's facility in US, is under the surveillance of FDA.

The surge comes on a day when Malaysia allotted its JV the site for a manufacturing unit, and a day after the firm reported Q2 earnings.

The pharmaceutical major’s Q1 net profit fell 90 per cent to Rs 126 crore as against a net profit of Rs 1,246 crore YoY.

According to an analyst, the launch of Absorica would greatly benefit Ranbaxy as there are only 2-3 players currently selling the product i...

Ranbaxy Laboratories has received US drug regulator's approval to relaunch one of its best selling brand in the US after being banned for n...

Ranbaxy laboratories has received an approval for an anti acne drug Absorica developed by US firm Cipher, the company said in a release to ...